| | Six Months Ended | |
(Unaudited, amounts in thousands) | | 10/28/17 | | 10/29/16 | |
Cash flows from operating activities | | | | | |
Net income | | $34,950 | | $35,113 | |
Adjustments to reconcile net income to cash provided by (used for) operating activities | | | | | |
Gain on disposal of assets | | (1,884 | ) | (62 | ) |
Gain on conversion of investment | | (2,204 | ) | — | |
Deferred income tax expense | | (403 | ) | 1,089 | |
Provision for doubtful accounts | | 74 | | (18 | ) |
Depreciation and amortization | | 15,869 | | 13,999 | |
Equity-based compensation expense | | 6,410 | | 5,880 | |
Pension plan contributions | | (2,000 | ) | (2,300 | ) |
Change in receivables | | 6,165 | | 784 | |
Change in inventories | | (4,096 | ) | (3,747 | ) |
Change in other assets | | (7,935 | ) | (1,806 | ) |
Change in payables | | 2,136 | | 1,549 | |
Change in other liabilities | | 4,142 | | 3,622 | |
Net cash provided by operating activities | | 51,224 | | 54,103 | |
| | | | | |
Cash flows from investing activities | | | | | |
Proceeds from disposals of assets | | 608 | | 143 | |
Proceeds from property insurance | | 1,485 | | — | |
Capital expenditures | | (16,372 | ) | (10,226 | ) |
Purchases of investments | | (18,507 | ) | (17,814 | ) |
Proceeds from sales of investments | | 11,529 | | 9,757 | |
Acquisitions, net of cash acquired | | (15,879 | ) | (15,997 | ) |
Net cash used for investing activities | | (37,136 | ) | (34,137 | ) |
| | | | | |
Cash flows from financing activities | | | | | |
Payments on debt | | (131 | ) | (156 | ) |
Stock issued for stock and employee benefit plans, net of shares withheld for taxes | | 356 | | 1,371 | |
Excess tax benefit on stock option exercises | | — | | 1,826 | |
Purchases of common stock | | (30,692 | ) | (19,766 | ) |
Dividends paid | | (10,648 | ) | (9,869 | ) |
Net cash used for financing activities | | (41,115 | ) | (26,594 | ) |
| | | | | |
Effect of exchange rate changes on cash and equivalents | | 865 | | (149 | ) |
Change in cash, cash equivalents and restricted cash | | (26,162 | ) | (6,777 | ) |
Cash, cash equivalents and restricted cash at beginning of period | | 150,859 | | 121,335 | |
Cash, cash equivalents and restricted cash at end of period | | $124,697 | | $114,558 | |
| | | | | |
Supplemental disclosure of non-cash investing activities capital expenditures included in payables | | $1,631 | | $681 | |